Products

Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    • Product Name: Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: admin@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    Specifications
    HS Code 353457
    Product Name Cicadae Periostracum Veterinary Grade API
    Intended Dosage Forms Tablets; Injections; Capsules; Powders; Granules; Premix; Solutions
    Source Dried molting exuviae of cicada species such as Cryptotympana pustulata and related Cicadidae
    Active Substances Standardized cicadae periostracum extract containing N-acetyldopamine oligomers, chitin, amino acids, and trace elements
    Physical Appearance Light brown to brownish-yellow fine powder with characteristic odor
    Solubility Partially soluble in water; soluble in dilute alkaline solutions and suitable organic solvent systems
    Pharmacological Properties Antipyretic, anticonvulsant, sedative, anti-inflammatory, and immunomodulatory activities
    Veterinary Indications Fever, convulsions, restlessness, inflammatory conditions, skin disorders, and respiratory irritation in livestock and companion animals
    Purity Assay ≥98% as cicadae periostracum extract determined by HPLC
    Loss On Drying ≤5.0%
    Particle Size 95% through 80 mesh for powder/granule/premix compatibility; micronized grades available for tablets and suspensions
    Heavy Metal Limit Total heavy metals ≤10 ppm; lead ≤2 ppm; arsenic ≤2 ppm; mercury ≤0.1 ppm
    Microbial Limits Total aerobic microbial count ≤1000 CFU/g; total yeast/mold ≤100 CFU/g; absence of Salmonella and Escherichia coli per veterinary pharmacopoeia
    Storage Conditions Preserve in tight, light-resistant containers; store in a cool, dry place below 25°C
    Shelf Life 36 months from date of manufacture when stored under recommended conditions
    Compatibility Notes Compatible with standard tablet, capsule, granule, premix, solution, and injection excipients at recommended pH ranges

    As an accredited Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Cicadae Periostracum Veterinary Grade API is packaged as 25 kg in moisture-proof, double-lined fiber drums, suitable for all dosage forms.
    Container Loading (20′ FCL) One 20′ FCL loaded with drums/cartons of Cicadae Periostracum API on pallets, secured, ventilated, moisture-proof, and sealed for safe veterinary-grade transport.
    Shipping Cicadae Periostracum Veterinary Grade API ships in sealed, moisture-proof, food-grade drums or bags with tamper-evident packaging. Transport in dry, ventilated, odor-free containers, protected from direct sunlight and extreme temperatures. Include Certificate of Analysis, SDS, and origin documentation. Avoid contact with toxic substances. Deliveries require traceability and proper handling per veterinary raw material guidelines.
    Storage Store in a cool, dry, well-ventilated area, tightly sealed in original, labeled containers. Protect from light, moisture, and excessive heat. Avoid direct contact with oxidizing agents. Keep away from contaminants, pests, and incompatible substances. Ensure proper handling per veterinary GMP guidelines. Use-audit stock rotation and prevent exposure to extreme temperature fluctuations.
    Shelf Life Shelf life is 24 months from manufacture date when stored unopened in original container, protected from moisture, heat, and light.
    Application of Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    On rotary tablet presses configured for veterinary oral solid dosage forms, the direct compression of Cicadae Periostracum extract requires particle engineering prior to die filling. The spray-dried extract typically exhibits a moisture content of 6.0% maximum when tested by loss on drying at 105°C in accordance with Chinese Veterinary Pharmacopoeia (CVP) general chapter 0831. Bulk density ranges from 0.45 g/mL to 0.55 g/mL, tapped density from 0.60 g/mL to 0.70 g/mL, and the angle of repose frequently exceeds 45°, indicating cohesive flow behaviour that must be corrected with colloidal silicon dioxide at 0.5–1.0 wt% and microcrystalline cellulose (PH102 grade) as a diluent at 35–45 wt%. Croscarmellose sodium at 2–4 wt% provides the disintegration capacity required by CVP chapter 0921, which specifies disintegration within 15 minutes in 0.1 M HCl at 37°C. Magnesium stearate is added at 0.5–1.0 wt% during the final 3 minutes of a twin-shell V-blender run to minimise punch sticking while avoiding overlubrication-induced tensile strength loss. Tablets are compressed to a target weight of 500 mg, with hardness controlled between 6 kp and 8 kp and friability below 1.0% after 100 rotations in a Roche friabilator. The 16-station rotary press operates at 20–30 rpm with a precompression force of 2–4 kN and a main compression force of 8–12 kN; higher main compression forces have been associated with lamination because the chitin-rich extract exhibits poor plastic deformation and limited particle-particle bonding under pressure. The finished tablets contain 250 mg of extract per unit and are administered via drinking water in poultry medicated water programmes after complete disintegration. Batch release testing includes assay of total amino acids by HPLC with pre-column derivatization using the extract ratio stated in the CVP monograph; assay acceptance criteria are set at 90.0–110.0% of label claim. Stability protocol follows VICH GL3, with storage at 25°C/60% RH; published data for Cicadae Periostracum tablet stability under tropical conditions is limited, so zone IVb testing at 30°C/75% RH is recommended before export to Southeast Asian and Latin American markets.

    What Constrains Sterile Filtration Throughput in Cicadae Periostracum Injection Solutions?

    The primary constraint on sterile filtration throughput is the residual colloidal chitin and thermally denatured protein fraction carried over from the crude exuviae. Water decoction is performed with purified water at a drug-to-solvent ratio of 1:8 w/v in a multi-function extraction tank (jacketed, 0.5 MPa steam) for 2 cycles of 60 minutes each at 95–100°C. The combined decoction is concentrated under vacuum (−0.08 MPa to −0.09 MPa, 60–70°C) to a relative density of 1.10–1.15 at 60°C. Ethanol precipitation is conducted by adding 95% ethanol to a final concentration of 60–70% v/v under continuous stirring at 4–8°C for 12 h to precipitate polysaccharides, high-molecular-weight proteins, and residual chitin filaments. The precipitate is removed by a tubular bowl centrifuge operated at 15,000 × g with a feed rate not exceeding 200 L/h to prevent sediment breakthrough. Activated charcoal (0.1% w/v, acid-washed, pharmaceutical grade) is added at 80°C for 30 minutes for depyrogenation and decolourisation, then removed by depth filtration through a 0.45 μm polypropylene filter cartridge followed by a 0.22 μm PES membrane in a two-stage sanitary filter housing. pH is adjusted to 5.5–6.5 with citrate buffer, and osmolality is corrected to 280–310 mOsm/kg with sodium chloride. Terminal sterilisation is performed in an autoclave at 121°C for 15 minutes (F0 ≥ 12) for 10 mL glass ampoules. The critical process parameter is the membrane throughput: when the extract contains more than 2 mg/mL of ethanol-insoluble residue, the 0.22 μm membrane must be replaced after 50–100 L/m² of filtration area, whereas a properly clarified batch can reach 300–500 L/m². The injection is administered intramuscularly to swine and cattle as adjunctive antipyretic therapy at a dose of 0.1 mL/kg body weight, with a withdrawal period determined by the importing country’s residue regulations.

    Unit OperationD50 (Micrometres)
    Raw decoction18–32
    After ethanol precipitation and centrifugation5.0–8.0
    After activated charcoal and depth filtration1.2–1.8
    After 0.45 μm cartridge0.6–0.9
    After 0.22 μm membrane<0.22

    Values represent typical filtration cascade data reported in membrane manufacturer technical bulletins for colloidal botanical extracts; site-specific validation under the batch production record is mandatory because chitin fibril aggregation varies with raw material collection season and drying history.

    Directly encapsulated Cicadae Periostracum extract for companion-animal use requires moisture content ≤ 4.0% and fill weight variation RSD ≤ 4.0% (CVP 0111) when filling size 0 hard gelatin capsules with 300 mg extract pre-blended with microcrystalline cellulose at 20–30 wt% and magnesium stearate at 0.5 wt%. The capsules are packed with desiccant in induction-sealed HDPE bottles; dissolution testing per CVP 0931 (paddle, 50 rpm, 0.1 M HCl) typically requires ≥ 70% released in 45 minutes, and the dose is titrated by the veterinarian due to limited published pharmacokinetic data in dogs and cats.

    When Dispersion of Spray-Dried Extract Fails on Poultry Water Medication Lines

    Spray-dried Cicadae Periostracum extract intended for direct addition to drinking water exhibits rapid sedimentation because the water-insoluble chitin fraction constitutes a significant portion of the crude material. Air-jet micronisation to a D90 of 50 μm reduces settling velocity but increases electrostatic cohesion and can form floating agglomerates in cold (10–15°C) drinking water. Addition of sodium lauryl sulfate at 0.5–1.0 wt% or polysorbate 80 at 0.2–0.5 wt% (where permitted by local veterinary regulations) lowers surface tension and improves wetting; however, polysorbate 80 at concentrations above 0.5% has been shown to increase biofilm formation in poorly cleaned water lines. The powder is blended in a ribbon blender at 30 rpm for 15 minutes after geometric dilution of the wetting agent onto a portion of the diluent (dextrose monohydrate or lactose). The final product is packed in 100 g sachets with a moisture barrier of PET/aluminium/LDPE laminate, and the loss on drying after blending is maintained at ≤ 6.0%. Reconstituted drinking water at 1 g/L has a pH of 6.0–7.5 and remains visually dispersible for 24 hours at 25°C if agitation is provided by a dosing pump; static water lines show sediment within 2–4 hours, which is an operational limitation rather than a formulation failure. This product is used in broiler and layer flocks during heat stress events or respiratory disease outbreaks, administered for 5–7 consecutive days, with a water withholding period of 12 hours before slaughter as specified by importing-country maximum residue limit schedules. The primary compliance standard is the Chinese Veterinary Pharmacopoeia monograph for Cicadae Periostracum Water-Soluble Powder, supplemented by ISO 22000 certification for the manufacturing plant.

    Because wet granulation introduces water into a hygroscopic matrix already prone to caking, the granulation endpoint for Cicadae Periostracum extract must be determined by real-time torque or power consumption on the mixer granulator rather than visual consistency. The extract powder is dry-blended with maize starch (10–15 wt%) and microcrystalline cellulose (10 wt%) in a high-shear mixer, then granulated with a 5% w/v starch paste or a 5–8% PVP K30 solution in isopropyl alcohol-water (70:30 v/v). The granulation liquid is sprayed at a rate of 0.2 L/min per 100 kg batch; endpoint is reached when impeller torque rises to 1.3–1.5 times the dry-mix baseline, corresponding to a granule moisture content of 8–12%. Wet granulates are transferred to a fluid bed dryer with inlet air temperature 60–70°C, product temperature 40–45°C, and air flow 1.5–2.0 m/s, drying to a final LOD of ≤ 4.0%. Dried granules are sieved through a 16-mesh screen to remove lumps and then through a 80-mesh screen to remove fines below 10%. Bulk density of the finished granules is 0.35–0.45 g/mL, with Carr index between 15–20, acceptable for die filling or sachet packaging. The granulated product is administered to pigs as a top dressing on feed at 2–5 g per animal per day for febrile respiratory conditions, mixed with a small amount of water to form a suspension if direct feeding is refused. Production is conducted under China Veterinary GMP for solid dosage forms, with cleaning validation for cross-contamination of the granulator and fluid bed based on swab recovery limits of 10 ppm.

    Feed Premix Carrier Selection and Blend Uniformity Parameters for Cicadae Periostracum

    In feed mills producing medicated premixes from botanical extracts, the low bulk density and fine particle size of spray-dried Cicadae Periostracum extract create segregation risks when blended with dense mineral carriers. Ground corn cob (bulk density 0.25–0.35 g/mL, D50 200–300 μm) and rice hulls (bulk density 0.20–0.30 g/mL, D50 150–250 μm) are preferred carriers because their particle size and density are closer to those of the extract (bulk density 0.45–0.55 g/mL, D50 25–50 μm), reducing percolation segregation. Calcium carbonate, though widely used for mineral premixes, has a bulk density of 0.9–1.1 g/mL and D50 of 20–40 μm, leading to rapid stratification of the extract to the top of the mixer within 5 minutes of mixing. The target inclusion rate is 0.5–2.0 kg of extract per tonne of finished feed for poultry and swine, depending on the indication; at inclusion rates below 0.5 kg/t, the coefficient of variation (CV) after mixing in a horizontal ribbon blender at 12–15 rpm for 15 minutes typically exceeds 7%, whereas higher inclusion rates achieve CV ≤ 5% when sampled at 10 locations (top, middle, bottom) immediately after discharge. Addition of 0.5–1.0 wt% vegetable oil (soybean or rapeseed) to the carrier before adding the extract reduces electrostatic dust and improves adhesion, but oil levels above 1.5% cause caking and impair silo flow. The premix is packed in 25 kg multi-wall paper bags with an inner polyethylene liner and stored at ≤ 25°C and ≤ 60% RH; moisture ingress above 8% triggers clumping and non-uniform distribution in the final feed mixer. Compliance falls under China Veterinary GMP for premixes and the CVP general chapter for premix uniformity; for export, EU Regulation 1831/2003 on feed additives does not directly apply unless the product is claimed as a zootechnical additive, but the importing country’s feed additive registration must be verified.

    CarrierBulk density (g/mL)D50 (μm)Angle of repose (°)CV after 15 min mixing (%)
    Ground corn cob0.25–0.35200–30030–384.0–6.0
    Rice hulls0.20–0.30150–25028–355.0–7.0
    Wheat middlings0.30–0.40100–20025–326.0–8.0
    Calcium carbonate0.9–1.120–4040–508.0–12.0

    Data sourced from carrier supplier technical bulletins and feed manufacturing handbooks; site-specific mixer validation is required because CV values depend on mixer fill level, blade clearance, and discharge sequence.

    Thermal Degradation Sensitivities in Oral Solution Pasteurization

    Oral solution compounding for veterinary use requires the extract to be fully dissolved or uniformly suspended, but the heat-sensitive nature of the nitrogenous components in Cicadae Periostracum extract limits the thermal treatment window. The extract is dispersed in purified water at 5% w/v and heated to 60°C for 30 minutes with continuous stirring to achieve dispersion without exceeding the degradation threshold; temperatures above 70°C for more than 15 minutes have been associated with visible darkening and increased insoluble matter, although published quantitative degradation kinetics for the specific marker compounds in Cicadae Periostracum are limited. The solution is cooled to 40°C before addition of preservatives: sodium benzoate at 0.1% w/v and potassium sorbate at 0.1% w/v are dissolved when the pH is adjusted to 5.0–5.5 with citric acid. Low-temperature long-time pasteurisation at 63°C for 30 minutes is preferred over high-temperature short-time processing because the latter accelerates chitin-protein complex formation that increases turbidity. Filtration through a 10 μm polypropylene bag filter removes coarse particles but does not provide sterility; therefore, the product is not intended for injection. The finished oral solution is packed in 100 mL and 500 mL high-density polyethylene bottles with child-resistant caps and a calibrated dosing cup. pH is monitored during stability at 25°C/60% RH for 24 months; a drift of more than 0.5 pH units indicates buffer exhaustion and requires reformulation. The solution is administered to piglets and calves for respiratory pyrexia at 1 mL per 10 kg body weight twice daily, mixed into drinking water or given orally by syringe. Compliance is governed by the veterinary oral solution monograph in the Chinese Veterinary Pharmacopoeia and by GMP Annex 15 for qualification and validation of the pasteurisation process.

    Free Quote

    Competitive Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615365186327

    Email: admin@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    `Cicadae Periostracum Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions` is supplied as a dry, non-sterile active pharmaceutical ingredient derived from the shed nymph exoskeleton of Cryptotympana atrata Fabricius (Cicadidae). Model designations separate the material by route risk: CP-V-API-TC for tablet and capsule direct compression, CP-V-API-INJ for injectable intermediates, and CP-V-API-PM for premix and granule carriers. The oral solid-dose fraction is released at D90 ≤ 180 µm, the injection intermediate at D90 ≤ 75 µm after jet milling, and the premix grade at D90 ≤ 250 µm. Release specifications include loss on drying ≤ 10.0% w/w for oral and premix grades and ≤ 8.0% w/w for the injection intermediate, total ash ≤ 7.0% w/w, acid-insoluble ash ≤ 1.0% w/w, and hot water-soluble extract ≥ 8.0% w/w. Veterinary use covers antipyretic and anticonvulsant supportive therapy in respiratory, ocular, and dermatological presentations.

    Compared with human-use or food-grade cicada slough, the veterinary-grade API is not extracted with ethanol, not sulfur-fumigated, and not exposed to irradiation. It is also not packaged as a dispensing granule with added dextrin. Unlike crude botanical powders, this API is dry-heat treated at 80–85 °C for 6–8 h without irradiation, ethylene oxide, or sulfite residues, and is controlled for microbial load and endotoxin according to route. A validated PCR method for species identification under ISO/IEC 17025 is used to verify Cryptotympana atrata identity; absence of common adulterant insect fragments is confirmed by microscopy.

    Which Route-Specific Release Parameters Separate the Injectable Intermediate From Tablet and Premix Fractions?

    The injectable intermediate is distinguished primarily by bacterial endotoxin control at ≤ 0.5 EU/mg when assayed by Ph. Eur. 2.6.14. Bioburden is held to ≤ 100 CFU/g by ISO 4833-1:2013 and yeast/mould count to ≤ 10 CFU/g by ISO 21527-2:2008. In contrast, the tablet/capsule fraction is released at ≤ 1000 CFU/g total aerobic count and ≤ 100 CFU/g yeast/mould count, and the premix fraction at ≤ 5000 CFU/g because of its dilution into feed. Heavy metal limits are set at ≤ 10 mg/kg for the injection intermediate and ≤ 20 mg/kg for oral and premix fractions, with ICH Q3D elemental impurity risk assessment applied to parenteral use. The injection fraction is also controlled for subvisible particle count after reconstitution: ≤ 100 particles/mL ≥ 10 µm and ≤ 5 particles/mL ≥ 25 µm by light obscuration particle counting at 25 °C.

    Jet milling of the injection intermediate is performed on a 0.1 MPa compressed-air micronizer at a feed rate of 20–25 kg/h. The D90 reduction from 180 µm to 75 µm increases specific surface area and water uptake rate; therefore the injection fraction is vacuum-dried to ≤ 8.0% w/w moisture and packed under nitrogen in 5–10 kg aluminium-laminated drums with desiccant. Subvisible particulate testing is performed after reconstitution in water for injection at 25 °C. The oral grade is not sterile and must not be used in sterile admixtures without validated terminal sterilization or aseptic filtration. Published data for this specific chitin-rich periostracum fraction at injection concentrations above 10 mg/mL is limited; formulation compatibility studies are required.

    Tablets and capsules produced on high-speed rotary presses require attention to bulk density and flow. The tablet/capsule fraction is blended with microcrystalline cellulose and 1.0–2.0% w/w magnesium stearate. Direct compression is limited by relatively high elastic recovery; slugging or wet granulation is recommended when API content exceeds 30% w/w. On a 16-station press at 30–40 rpm, tablets with hardness 60–80 N show friability < 0.8% by USP <1216> when granule moisture is kept at 2.5–3.5% w/w. Uncoated tablets disintegrate in < 15 min in water at 37 °C by USP <701>. Capsule filling on a dosator-style machine at 60,000 capsules/h requires D90 ≤ 150 µm and bulk density ≥ 0.40 g/mL to limit weight variation to ±5%. Slugging is performed at 12–18 kN on a 19 mm flat-faced tool; slugs are milled through a 1.0 mm screen, producing granule D50 180–250 µm. Dissolution of marker amino acids is not less than 75% in 45 min by USP <711> apparatus II at 50 rpm in 0.1 M HCl.

    Premix processing uses a 2–10% w/w API loading in dextrose or whey carrier. The premix fraction retains ≤ 5% w/w on a 250 µm sieve to prevent nozzle occlusion in poultry nipple drinker lines. Hot water extraction for drinking water solutions is performed at 60–70 °C for 30 min and filtered through 10 µm nylon mesh before metering pump delivery.

    When Preblending for Capsule Filling, Flow and Compaction Parameters Must Be Confirmed

    Because chitin-rich periostracum powders can exhibit angle of repose above 45° at moisture content above 10% w/w, preblending must include flow-aid addition. Silicified microcrystalline cellulose at 10–20% w/w or colloidal silicon dioxide at 0.5–1.0% w/w reduces angle of repose to 35–38°. Compressibility by Hausner ratio remains 1.25–1.35 for the direct-compression grade. If the preblend is stored above 60% RH, moisture re-equilibration increases caking tendency and weight variation; pre-drying is required in such conditions. The direct-compression fraction should be charged into the hopper at 20–25 °C and ≤ 50% RH to limit static adhesion and punch filming.

    Tablet press turret speed above 45 rpm is not recommended without a forced feeder because the flow function coefficient falls below 4.0 at higher humidity. For capsule filling, the powder bed height in the dosator chamber is maintained at 60–70% of chamber volume. Weight variation above ±5% at 60,000 capsules/h indicates segregation or moisture uptake; both require immediate halt and reconditioning. The premix and granule fraction is dry-blended with dextrose or whey carrier at 2–10% w/w API loading. Hot water extraction for drinking water solution is performed at 60–70 °C for 30 min and filtered through 10 µm nylon mesh before metering pump delivery.

    Premix, Granule, and Solution Compatibility Boundary Conditions

    The API is stable as a dry powder at 25 ± 2 °C and ≤ 60% RH for 24 months in sealed polyethylene-lined drums. Aqueous extracts are physically unstable below pH 3.5 and above pH 9.0, with visible precipitation. Strong oxidizing agents and cationic surfactants should not be introduced into medicated drinking water. Alkaloidal precipitation agents such as tannic acid are incompatible. The material is not recommended for dry-heat terminal sterilization above 120 °C because of darkening and loss of water-soluble extract. High-shear blending above 45 °C may agglomerate chitin particles and reduce sieve passage. In feed premixes, organic acid carriers below pH 4.5 reduce dispersibility in water; a neutral carrier is preferred for liquid dosing systems.

    For solution preparation, extraction must be conducted in stainless steel or glass-lined vessels; prolonged contact with unlined mild steel can raise iron content above the 10 mg/kg parenteral limit. The extract is filtered through 0.45 µm PVDF before final aseptic filtration through 0.22 µm membrane for injectable solutions. Filter loading should not exceed 100 L/m² at 0.1 MPa for the 0.22 µm membrane to avoid premature fouling from chitin microparticles.

    Route-specific release comparison by model code
    Parameter CP-V-API-TC CP-V-API-INJ CP-V-API-PM
    Particle size D90 ≤ 180 µm ≤ 75 µm ≤ 250 µm
    Loss on drying ≤ 10.0% w/w ≤ 8.0% w/w ≤ 10.0% w/w
    Total aerobic count ≤ 1000 CFU/g ≤ 100 CFU/g ≤ 5000 CFU/g
    Yeast/mould ≤ 100 CFU/g ≤ 10 CFU/g ≤ 100 CFU/g
    Bacterial endotoxins Not specified ≤ 0.5 EU/mg Not specified
    Heavy metals ≤ 20 mg/kg ≤ 10 mg/kg ≤ 20 mg/kg

    Thermal Degradation Limits Dry-Heat Sterilization of Chitin-Rich Fractions

    Dry-heat treatment at 80–85 °C for 6–8 h achieves microbial reduction without marked extract loss, but exposure above 120 °C for 2 h reduces water-soluble extract by 10–15% relative to untreated material and darkens the powder. Moist heat terminal sterilization at 121 °C for 15 min is not recommended for the dry API because of clumping; if required for a finished injectable solution, it must be performed after filtration and pH adjustment to 5.5–7.0. The injection intermediate is not sterile and is not depyrogenated as supplied. Downstream aseptic processing or terminal sterilization of the finished dosage form is mandatory. Residual water after vacuum drying at 60 °C for 4 h should be below 8.0% w/w before packaging to prevent microbial regrowth and clumping.

    The dry heat process is validated by bioburden reduction studies using heat-resistant spore indicators; the D-value for Bacillus atrophaeus at 85 °C is 2.5–3.0 h in this matrix. Process lethality is therefore limited; the terminal microbial reduction step is not equivalent to sterilization.

    Compliance and test method matrix
    Standard/method Application Acceptance
    ISO 4833-1:2013 Total aerobic microbial count Route-specific limits per release table
    ISO 21527-2:2008 Yeast and mould count ≤ 100 CFU/g oral/premix; ≤ 10 CFU/g injection
    ISO 6579-1:2017 Salmonella spp. Absent in 25 g
    Ph. Eur. 2.6.14 Bacterial endotoxins ≤ 0.5 EU/mg injection grade
    USP <1216> Tablet friability < 0.8%
    USP <731> Loss on drying ≤ 10.0% or ≤ 8.0% per grade
    Top